[go: up one dir, main page]

ATE461213T1 - Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung - Google Patents

Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung

Info

Publication number
ATE461213T1
ATE461213T1 AT01952590T AT01952590T ATE461213T1 AT E461213 T1 ATE461213 T1 AT E461213T1 AT 01952590 T AT01952590 T AT 01952590T AT 01952590 T AT01952590 T AT 01952590T AT E461213 T1 ATE461213 T1 AT E461213T1
Authority
AT
Austria
Prior art keywords
fgf23
methods
growth factor
fibroblast growth
relates
Prior art date
Application number
AT01952590T
Other languages
English (en)
Inventor
Michael Econs
Ken White
Tim Strom
Thomas Meitinger
Original Assignee
Advanced Res & Tech Inst
Univ Muenchen L Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE461213(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Advanced Res & Tech Inst, Univ Muenchen L Maximilians filed Critical Advanced Res & Tech Inst
Application granted granted Critical
Publication of ATE461213T1 publication Critical patent/ATE461213T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
AT01952590T 2000-07-19 2001-07-10 Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung ATE461213T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21913700P 2000-07-19 2000-07-19
PCT/US2001/021738 WO2002008271A1 (en) 2000-07-19 2001-07-10 Novel fibroblast growth factor (fgf23) and methods for use

Publications (1)

Publication Number Publication Date
ATE461213T1 true ATE461213T1 (de) 2010-04-15

Family

ID=22818027

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01952590T ATE461213T1 (de) 2000-07-19 2001-07-10 Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung

Country Status (11)

Country Link
US (5) US7223563B2 (de)
EP (2) EP2184296A1 (de)
JP (2) JP2004504063A (de)
KR (2) KR20090036151A (de)
CN (1) CN1446227B (de)
AT (1) ATE461213T1 (de)
AU (2) AU7332301A (de)
CA (1) CA2418215A1 (de)
DE (1) DE60141582D1 (de)
ES (1) ES2340662T3 (de)
WO (1) WO2002008271A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
WO2001066595A2 (en) * 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
EP1310554B1 (de) * 2000-08-11 2010-05-26 Kyowa Hakko Kirin Co., Ltd. DEN PHOSPHORSÄURE-METABOLISMUS, DEN KALZIUM-METABOLISMUS, VERKALKUNG UND DEN VITAMIN D-METABOLISMUS KONTROLLIERENDE POLYPEPTIDE SOWIE FüR DIESE KODIERENDE DNA-MOLEKÜLE
US7226749B2 (en) 2000-12-05 2007-06-05 Zahradnik Richard J Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
US6838264B2 (en) 2000-12-05 2005-01-04 Immutopics, Inc. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
WO2002052009A1 (fr) * 2000-12-26 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Mutant de la proteine fgf23 humaine reduisant le taux de phosphore dans le sang
EP1381683A2 (de) * 2001-04-26 2004-01-21 Geneprot, Inc. Menschliche fibroblasten-wachstumsfaktor-verwandte zusammensetzungen
ES2331414T3 (es) 2001-12-28 2010-01-04 Kyowa Hakko Kirin Co Ltd Anticuerpos contra el factor 23 de crecimiento de fibroblastos.
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
DE602004032457D1 (de) * 2003-11-07 2011-06-09 Novartis Ag Nten
IL161886A0 (en) * 2004-05-09 2005-11-20 Technion Res & Dev Foundation Development of inducers of udp-n-acetyl-alphad-galactosamine: polypeptide n-acetylgalactosami-nyltransferase 3(ppgantase
EP1745151B1 (de) * 2004-05-09 2009-12-02 Technion Research And Development Foundation, Ltd. Verfahren in zusammenhang mit anomalen phosphatmetabolismus assoziierten erkrankungen
US20060236220A1 (en) * 2005-04-18 2006-10-19 Clearplay, Inc. Apparatus, System and Method for Associating One or More Filter Files with a Particular Multimedia Presentation
KR100760525B1 (ko) * 2006-04-13 2007-10-04 김재만 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법
US8012694B2 (en) 2006-09-14 2011-09-06 Immutopics, Inc. Assay for the detection of phosphorylated PTH
EP2115168A1 (de) 2007-01-22 2009-11-11 Medizinische Universität Innsbruck Neue marker für chronische nierenerkrankung
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2009091556A2 (en) * 2008-01-17 2009-07-23 The General Hospital Corporation Diagnostic methods and kits using fibroblast growth factor-23
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
KR101660544B1 (ko) * 2008-04-29 2016-09-27 노파르티스 아게 섬유모세포 성장 인자 수용체의 키나제 활성에 대한 조정을 모니터링하는 방법 및 상기 방법의 용도
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
KR101882533B1 (ko) 2010-08-31 2018-07-26 교와 메덱스 가부시키가이샤 섬유아세포 증식 인자-２３ 의 측정 방법 및 측정 시약
WO2012055096A1 (zh) * 2010-10-27 2012-05-03 温州医学院生物与天然药物开发中心有限公司 抗fgf-23抗体的制备方法及用途
EP2723391B1 (de) 2011-06-24 2018-06-13 University of Miami Fibroblastenwachstumsfaktorrezeptor-inhibitoren zur behandlung von erkrankungen
PE20141727A1 (es) 2011-07-01 2014-11-26 Ngm Biopharmaceuticals Inc Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
CA2892152A1 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9925242B2 (en) 2012-12-27 2018-03-27 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
CN106164255B (zh) * 2013-09-20 2020-02-14 隆萨有限公司 细胞的核重编程的方法
MX377380B (es) 2013-10-28 2025-03-10 Ngm Biopharmaceuticals Inc Modelos de cáncer y métodos asociados.
AU2015209131B2 (en) 2014-01-24 2020-06-25 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA2943361A1 (en) 2014-03-28 2015-10-01 New York University Fgf23 fusion proteins
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015191312A1 (en) * 2014-06-09 2015-12-17 Ultragenyx Pharmaceutical Inc. The effective and efficient control of serum phosphate for optimal bone formation
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
UA123763C2 (uk) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
MX2017007303A (es) 2014-12-04 2017-08-25 Novartis Ag Metodos y composiciones que utilizan polipeptidos variantes klotho.
CN105699664A (zh) * 2015-04-13 2016-06-22 陈柏龄 Fgf23检测试剂盒及其制备方法
AU2016284696B2 (en) 2015-06-25 2021-10-28 Amyris, Inc. Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
KR102641031B1 (ko) * 2017-03-28 2024-02-28 아지노모토 가부시키가이샤 미분화 유지 배지 첨가제
US12498366B2 (en) 2017-05-31 2025-12-16 Canon Medical Diagnostics Corporation Measurement method for fibroblast growth factor-23 by forming immunocomplexes
WO2020047475A1 (en) * 2018-08-30 2020-03-05 The Uab Research Foundation Drug screening for fgf23-fgfr4 inhibitors
JP2022527790A (ja) * 2019-03-29 2022-06-06 アターガ，エルエルシー 抗ｆｇｆ２３抗体分子
EP3956354A1 (de) * 2019-04-19 2022-02-23 Genethon Gentherapie von hypophosphatämischen erkrankungen im zusammenhang mit fibroblastenwachstumsfaktor 23

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
CA2160583A1 (en) 1993-04-16 1994-10-27 Stanley A. Plotkin Recombinant cytomegalovirus vaccine
US5693775A (en) * 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
CA2383254A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1690872A3 (de) * 1999-12-01 2006-08-23 Genentech, Inc. Zusammensetzung und Verfahren zur Diagnose eines Tumors
EP1252305A2 (de) 1999-12-08 2002-10-30 Genset Cdnas in vollständiger länge, die für potentiell sekretierte proteine kodieren
CA2396401A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf12
AU2001239765A1 (en) 2000-02-14 2001-08-27 Smith Kline Beecham Corporation Novel compounds
AU3976701A (en) * 2000-02-15 2001-08-27 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
WO2001066595A2 (en) * 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
WO2002076467A1 (en) * 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism

Also Published As

Publication number Publication date
US7745406B2 (en) 2010-06-29
CN1446227B (zh) 2011-10-05
AU2001273323B2 (en) 2005-11-10
US8586317B2 (en) 2013-11-19
JP2004504063A (ja) 2004-02-12
EP2184296A1 (de) 2010-05-12
CA2418215A1 (en) 2002-01-31
ES2340662T3 (es) 2010-06-08
KR20090036151A (ko) 2009-04-13
JP2008194039A (ja) 2008-08-28
AU7332301A (en) 2002-02-05
US20080241946A1 (en) 2008-10-02
US20030181379A1 (en) 2003-09-25
KR100924183B1 (ko) 2009-10-28
US20020156001A1 (en) 2002-10-24
EP1303536B1 (de) 2010-03-17
CN1446227A (zh) 2003-10-01
DE60141582D1 (de) 2010-04-29
EP1303536A1 (de) 2003-04-23
EP1303536A4 (de) 2005-01-05
WO2002008271A1 (en) 2002-01-31
US7314618B2 (en) 2008-01-01
US20090311792A1 (en) 2009-12-17
US20120064544A1 (en) 2012-03-15
KR20030029111A (ko) 2003-04-11
US7947810B2 (en) 2011-05-24
US7223563B2 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
DE60141582D1 (de) Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
WO2001066595A3 (en) Human fgf-23 gene and gene expression products
DK1218509T3 (da) Fibroblast vækstfaktorlignende polypeptider
PT1232264E (pt) Gene fgf-21 humano e produtos da expressão do gene
ATE269102T1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
Armstrong et al. House-yard burials of enslaved laborers in eighteenth-century Jamaica
LV10308A (lv) Ciliarais neirotropais faktors
WO2001066596A3 (en) Human fgf-23 gene and gene expression products
ATE304362T1 (de) Pharmazeutische zusammensetzung zur stimulierung des wachstums von gram-positiven bazillen und zur erhöhung der azidität der vagina und ihre verwendung
IS7770A (is) Hlutleysandi mótefni gegn GDF-8 og notkun theirra
EP1451578A4 (de) Angiopoetinähnliches protein 3 angptl3 enthaltende zusammensetzung und verfahren zu dessen verwendung
BR0213958A (pt) Métodos para tratar diabete e condições relacionadas com base em polimorfismos no gene tcf1
ATE466106T1 (de) Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
ATE469217T1 (de) Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
BR0116507A (pt) Fatores do crescimento de fibroblastos
EE200100472A (et) Polüpeptiid, antikehad, lahustuv polüpeptiid, polü- või oligonukleotiid ja meetod diferentsiaalseltekspresseerunud DNA järjestuste spetsiifiliseks identifitseerimiseks
WO2002022871A3 (en) Polymorphic bone morphogenetic protein 2
DE69838509D1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
ATE169343T1 (de) Gemeinschaftlich verwendete genetische marker zur diagnostik der alzheimerschen krankheit, methode und diagnostischer reagenziensatz
AUPN154295A0 (en) Nucleic acid molecule encoding a protein with avian gamma-interferon activity
DE69903278D1 (de) Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit
EP1009768A4 (de) Persephin und verwandte wachstumsfaktoren
DE60123109D1 (de) Mit schizophrenie in zusammenhang stehendes gen, das für ein potential-abhängiges ionkanal kodiert
TW200734638A (en) Method for the diagnosis of thromboembolic and coronary heart diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties